Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP12 | P39900 | 4/20 | 0.43 |
| ▸ | MMP13 | P45452 | 4/20 | 0.43 |
| ▸ | MMP14 | P50281 | 4/20 | 0.43 |
| ▸ | MMP1 | P03956 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2500403 | 0.86 | MMP2 (0.53) | MAPK1GSK3BALDH1A1TRPA1HIF1A | |
| SCHEMBL5098746 | 0.84 | MMP2 (0.58) | ALDH1A1TRPA1TDP1MMP2MMP12 | |
| SCHEMBL6026669 | 0.83 | CA1 (0.54) | MAPK1GSK3BALDH1A1TRPA1HIF1A | |
| SCHEMBL7196858 | 0.79 | MAPT (0.61) | MAPK1GSK3BALDH1A1TRPA1HIF1A | |
| SCHEMBL3673843 | 0.79 | L3MBTL1 (0.42) | MAPK1GSK3BALDH1A1TRPA1HIF1A | |
| SCHEMBL20565283 | 0.79 | MMP2 (0.41) | ALDH1A1TDP1MMP2MMP12MMP13 | |
| SCHEMBL4284771 | 0.76 | PPARG (0.55) | MAPK1ALDH1A1HIF1AMAPTTDP1 | |
| SCHEMBL7619216 | 0.76 | SRD5A2 (0.49) | ALDH1A1TRPA1MAPTMEN1CYP3A4 | |
| SCHEMBL9279658 | 0.74 | KDM4E (0.43) | MAPK1GSK3BALDH1A1TRPA1HIF1A | |
| SCHEMBL5680692 | 0.74 | BCL2 (0.45) | ALDH1A1HIF1ATDP1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998415-B2 | Pyrazolyl derivatives; antiinflammatory agents for inflammation; antiallergens for asthma | PHARMACIA CORPORATION (US) | 2006-02-14 | — | — | US | disclosed |
| US-20040147565-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. | 2004-07-29 | — | — | US | disclosed |
| EP-0828736-B1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-0995747-B1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | SEARLE & CO (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6403644-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-6177466-B1 | Sulfonylamino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0995747-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147565-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | MAPK1 2297/4885GSK3B 3989/4885ALDH1A1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.